PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Cancer Prev Res (Phila). Author manuscript; available in PMC 2012 September 1.
Published in final edited form as:
PMCID: PMC3168068
NIHMSID: NIHMS305960

Iron homeostasis and distal colorectal adenoma risk in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial

Abstract

Red meat consumption has been positively associated with colorectal cancer; however, the biologic mechanism underlying this relationship is not understood. Red meat is a major source of iron, which may play a role in colorectal carcinogenesis via increased crypt cell proliferation, cytotoxicity, and endogenous N-nitrosation. In a nested case-control study within the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, we prospectively evaluated multiple iron exposure parameters, including dietary intake and serum measures of iron, ferritin, transferrin, total iron binding capacity (TIBC), and unsaturated iron binding capacity (UIBC) in relation to incident colorectal adenoma in 356 cases and 396 matched, polyp-free controls. We also investigated variation in eight key genes involved in iron homeostasis in relation to colorectal adenoma in an additional series totaling 1,126 cases and 1,173 matched controls. We observed a positive association between red meat intake and colorectal adenoma (odds ratio comparing extreme quartiles [ORq4-q1] = 1.59, 95% confidence interval [CI]: 1.02-2.49, P-trend = 0.03). Serum TIBC and UIBC were inversely associated with colorectal adenoma (ORq4-q1 = 0.57, 95% CI: 0.37-0.88, P-trend = 0.03; and ORq4-q1 = 0.62, 95% CI: 0.40-0.95, P-trend = 0.04, respectively). Colorectal adenoma was not associated with serum ferritin, iron, or transferrin saturation, or with polymorphisms in genes involved in iron homeostasis. Serum TIBC and UIBC, parameters which have a reciprocal relationship with overall iron load, were inversely related to colorectal adenoma, suggesting that individuals with lower iron status have a reduced risk of colorectal adenoma.

Keywords: Diet, meat, iron, colorectal, adenoma, cancer

Introduction

There is considerable epidemiologic evidence to suggest that intake of red meat, but not white meat, is positively associated with colorectal cancer (1). Red and white meat differ primarily in their content of iron; specifically, the concentration of iron in red meat is approximately ten-fold higher than that of white meat (2, 3). Heme iron, which is iron bound to a porphyrin ring such as in hemoglobin or myoglobin, is the predominant source of iron in red meat and is more readily absorbed in the intestine than non-heme iron (4).

A large body of laboratory data supports a role for iron in colorectal tumorigenesis. In animal models, for example, iron supplementation increases crypt cell proliferation in the large intestine (5), while rodents inoculated with colon adenocarcinoma cells have decreased tumor growth when fed an iron-deficient diet (6). Furthermore, iron supplementation enhances the rate of tumor growth (7, 8), and in vitro studies have demonstrated that tumor cells have a greater ability than normal cells to grow and/or survive in the presence of high levels of iron (9). Humans consuming heme iron specifically exhibit increased endogenous formation of N-nitroso compounds (NOCs) (10), which are known mammalian carcinogens able to target many tissues, including the colorectum (11).

In contrast to the relative abundance of laboratory data supporting a role for iron in colorectal tumorigenesis, epidemiologic data on iron and colorectal neoplasia is sparse. The few published studies that have addressed questionnaire-assessed dietary iron in relation to colorectal neoplasia resulted in inconsistent findings, possibly because of the methodologic inability to assess heme iron intake specifically (12, 13, 14). In addition, although several prospective studies have evaluated the association of serologic markers of iron status with colorectal neoplasia, the results are conflicting (15). Genetic studies of iron metabolism and colorectal neoplasia are also limited. Carriage of a set of rare mutations in the HFE gene, which confer increased risk of developing hemochromatosis, a syndrome characterized by elevated body iron stores, have been linked to increased risk of colorectal cancer in one study (16), though subsequent investigations failed to replicate this finding (17, 18, 19).

To our knowledge, no single study has simultaneously investigated dietary iron intake, serum iron indices and variation in multiple genes governing iron homeostasis in relation to colorectal neoplasia. We sought to examine whether increased iron exposure, as determined from diet, serologic markers and genetic variation, was associated with the risk of colorectal adenoma, an established colorectal cancer precursor.

Methods

Study Population

Our study was nested within the screening arm of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, which is a large, randomized controlled trial designed to test the efficacy of cancer screening and to investigate early markers and etiology of cancer (20, 21, 22). Between 1993 and 2001, approximately 155,000 men and women aged 55-74 years who had no prior history of prostate, lung, colorectal or ovarian cancer were enrolled from 10 U.S centers. Those randomly assigned to the screening arm (n = 77,465) were offered a flexible sigmoidoscopy examination of the distal colorectum (60cm) at study entry, of which 83% (n = 64,658) were compliant and 89% (n = 57,559) of these were considered successful (insertion to at least 50cm with greater than 90% of mucosa visible or a suspect lesion identified). If neoplastic lesions were detected, participants were referred for subsequent colonoscopic examination. All available medical and pathologic reports on follow-up were obtained and coded by trained medical record abstractors. The institutional review boards of the U.S. National Cancer Institute and the 10 screening centers approved the study and all participants provided informed consent.

Study Sample

We selected participants assigned to the screening arm of the PLCO Cancer Screening Trial between September 1993 and September 1999 who had undergone a successful sigmoidoscopy, completed the baseline risk factor questionnaire and the dietary questionnaire, and provided a blood sample for use in etiologic studies (n = 42,037). We excluded 4,834 individuals due to a self-reported history of any of the following: Crohn's disease, ulcerative colitis, familial polyposis, Gardner's syndrome, colorectal polyps or cancer (except basal-cell skin cancer).

Among those who had a negative sigmoidoscopy result (i.e. no polyp or other suspect lesion detected) at the baseline screen (T0), we identified 356 incident colorectal adenoma cases at the follow-up sigmoidoscopy screening exam (administered either 3 or 5 years later, T3 or T5). The cases were matched (on age, gender, ethnicity, study center, season of blood draw and whether their follow-up sigmoidoscopy was after three or five years) to 396 controls who were polyp-free at both the baseline screen (T0) and the follow-up screen (T3 or T5). This group of cases and controls is referred to as the ‘serologic sample’.

For analysis of variation in genes related to iron homeostasis and colorectal adenoma, we additionally selected a set of advanced colorectal adenoma cases (hereafter termed ‘genotyped sample’ and defined as adenomas with high-grade dysplasia or villous components or ≥ 1 cm), identified at the baseline screen (T0). A full description of the selection of these study subjects has been published elsewhere (23); in brief, of the 1,234 individuals who had at least one distal advanced colorectal adenoma at the baseline screen, we randomly selected 772 cases and matched by gender and ethnicity to 777 of the 26,651 control participants with a negative sigmoidoscopy examination.

Dietary Iron Assessment

Usual diet over the twelve months prior to enrollment was assessed on the day of sigmoidoscopy using a 137-item food frequency questionnaire (FFQ). Heme iron intake was estimated using the FFQ in conjunction with a heme iron database based on measured values from various meat types cooked by different methods and to varying doneness levels (24).

Serum Iron Indices

Serum iron parameters were measured in the incident colorectal adenoma cases and their matched controls. To investigate whether the serum iron parameters are stable over time in a small pilot, we sampled a random sub-set of 50 incident cases (pilot cases) and 30 controls (pilot controls) with available blood specimens at both baseline (T0) and five years in to the trial (T5).

Serum ferritin, a marker of stored iron, was measured using an immunoradiometric assay kit (Count-A-Count Ferritin IRMA: Diagnostic Products Corporation, Los Angeles, CA). Serum iron and unsaturated iron binding capacity (UIBC) were assessed using a standard ferrozine-based iron colormetric assay (Olympus AU 400e auto analyzer). Total iron binding capacity (TIBC), calculated as the sum of serum iron plus UIBC, is a measure of the iron binding capacity within the serum and reflects the availability of iron binding sites on transferrin. Transferrin saturation indicates the extent to which transferrin has vacant iron-binding sites (i.e. low transferrin saturation indicates a high proportion of vacant iron-binding sites) and was calculated as serum iron divided by TIBC. In addition, because ferritin is an acute phase protein, and the inflammatory state is related to both body iron stores and colorectal neoplasia (25), we assessed C-reactive protein (CRP) levels as a marker of inflammation, using a latex particle enhanced immunotubidimetric assay kit (K-ASSAY CRP Ultra (EQual Diagnostics, Exton PA). All serum samples were analyzed blinded to case-control status and each batch contained 10% randomly inserted quality control serum samples that have been used in other studies (26). The coefficient of variation (CV) for all analytes was less than 6.4%.

SNP Selection and Genotyping

We selected eight genes that play key roles in the uptake, absorption and metabolism of dietary iron: transferrin (TF), transferrin receptor (TFRC), heme oxygenase (HMOX1), solute carrier family 40 - ferroportin (SLC40A1), solute carrier family 11 - proton-coupled divalent metal ion transporters (SLC11A2), hepcidin antimicrobial peptide (HAMP), aconitase 1 (ACO1), and haptoglobin (HP01) – see Supplementary Table S1. We used dbSNP (http://www.ncbi.nlm.nih.gov/SNP/), SNP500 (http://snp500cancer.nci.nih.gov/) and SNPper (http://snpper.chip.org/) and from literature searches on iron metabolism to select SNPs located within exonic gene regions, putative regulatory regions and exon-intron junctions with priority given to those linked with serum or tissue iron levels, or colorectal neoplasia, in previous studies. The selected SNPs were verified in a panel of 102 individuals of self-described Caucasian (n = 31), African-American (n = 24), Hispanic (n = 23) and Pacific Rim (n = 24) ethnicity (27) by re-sequencing approximately 300bp of DNA either side of the putatively polymorphic locus. SNPs with a minor allele frequency of 5% or more among Caucasians (which represent 93% of our study sample) were chosen for genotyping in the current study.

DNA was extracted from buffy coat or whole blood samples using routine methods. Genotyping was performed at the Core Genotyping Facility of the Division of Cancer Epidemiology and Genetics, National Cancer Institute using TaqMan (Applied Biosystems, Foster City, CA). Protocols for each specific assay are available at the following web site: http://snp500cancer.nci.nih.gov (27). For validation purposes, TaqMan assays were initially applied to the 102 individuals with sequence information and were subsequently applied to the PLCO Cancer Screening Trial samples only if sequencing and TaqMan results were 100% concordant, otherwise a new TaqMan assay was designed. For 6 cases and 6 controls, no genotype data were available due to insufficient DNA yields, DNA that did not amplify, or failure of unambiguous genotyping. Blinded quality control samples, comprising DNA from 40 individuals, were assayed between 2 and 4 times and these genotypes were found to be 100% concordant. All polymorphic loci analyzed in this study had genotypic distributions consistent with Hardy-Weinberg equilibrium among the controls.

Statistical Analysis

The demographic characteristics and dietary covariates of those with and without colorectal adenoma were compared using the χ2 test for categorical variables and the Wilcoxon rank sum test for continuous variables. For the pilot study in which we evaluated temporal stability of iron parameters in cases and controls, we assessed differences in medians between T0 and T5 using the Wilcoxon-Sign Rank test. To estimate the reliability of a one-time measurement of serum iron levels, we compared iron parameter concentrations at T0 and T5 in a sub-set of control participants (n=30) by calculating the intra-class correlation coefficient (ICC). Since the serum iron measurements were not normally distributed in the control sample, the data were logarithmically transformed to approximate normality and log values were used to derive ICCs. Intra-individual and inter-individual variances for serologic measures were estimated using random effects models, and the ICC was derived from these values. Unconditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI) for the association between the dietary variables, as well as the serologic parameters, with colorectal adenoma risk. The dietary variables were nutrient density energy adjusted and quartile cut-points were based on reported intake in the controls. The serologic data were analyzed as both continuous, log-transformed variables and as categorical variables based on the distribution of quartile cut-points in the controls. In addition to the matching factors, all models were adjusted for an a priori-determined set of colorectal neoplasia risk factors, including: use of non-steroidal anti-inflammatory drugs (NSAIDs), family history of colorectal cancer, educational attainment, use of hormone therapy (females only), and smoking (never, former or current smoker). Inclusion of other potential covariates such as body mass index, self-reported history of diabetes, serum CRP level, alcohol consumption, physical activity, and intake of fiber, calcium, folate, vitamin D, saturated fat and red meat, did not change the risk estimates by more than 10% and were therefore not included in the final multivariable models. Tests for trend were calculated using a single ordinal variable corresponding to the median values for each quartile, which was entered into the multivariable model as a continuous variable.

The associations between genotypes and colorectal adenoma were estimated using unconditional logistic regression, with the most common genotype serving as referent. All genetic analyses were adjusted for age; other colorectal adenoma risk factors were evaluated as potential covariates but did not alter the risk estimates by 10% or more; therefore, they were not included in the final models. To calculate P-values for trend, we assigned the ordinal values 0, 1, and 2 to the most prevalent genotypes in rank order of homozygous for the common allele, heterozygous and homozygous for the rare allele, respectively.

We also investigated the association between specific haplotypes and colorectal adenoma. Linkage disequilibrium between the SNPs was assessed using r2 and D′ statistics and visualized using Haploview (28). Haplotype blocks were characterized among the controls according to the method of Gabriel et al. (29) and haplotype distribution and frequencies were assessed using PHASE software (30). We used logistic regression to estimate the associations between each haplotype and colorectal adenoma using the most common haplotype as the reference category. Due to very high linkage disequilibrium within blocks, there was little phase ambiguity in haplotype reconstruction and thus the related statistical uncertainty was ignored (31).

The relation between genotypes and serum iron parameters were assessed in the controls in the serologic sample using ANOVA models adjusted for age. All reported P-values are two-sided and analyses were conducted using SAS software (SAS Institute, Cary, NC, version 9).

Results

The serologic sample consisted of 356 (232 male and 124 female) incident adenoma cases, of which 143 were advanced (103 male and 40 female), and 396 (259 male and 137 female) controls. The additional genotyped sample consisted of 770 (533 male and 237 female) advanced adenoma cases and 777 (536 male and 241 female) controls. In both the serologic and genotyped samples, the cases were more likely to be current smokers, more likely to have family history of colorectal cancer and more likely to consume alcohol, but they were less physically active and less likely to be regular users of NSAIDs; however, these differences between cases and controls were not all statistically significant in both groups (Table 1). Red meat and heme iron intake was slightly higher in the cases compared to the controls in both serologic and genotyped samples, although this difference was not statistically significant. Cereals and bread accounted for 37% of the total dietary iron intake, whereas red meat only accounted for 8%; other foods contributing significantly to this variable included vegetables (15%), fruit (4%), white meat (4%), pasta (4%), orange/grapefruit juice (3%), rice (2%), coffee (2%), and milk (1%). Dietary iron was lower in the cases compared to the controls in the genotyped sample (P = 0.05). Serum TIBC and UIBC were lower in cases compared to controls (P = 0.07, and P = 0.05, respectively, Table 1). The Spearman's rank correlations between the serum iron indices and dietary variables in the controls indicated that heme iron intake was moderately correlated with serum ferritin levels (r = 0.25), but none of the other iron indices were correlated with dietary iron intake (Table 2).

Table 1
Baseline characteristics of the study sample by colorectal adenoma cases and controls in the PLCO Cancer Screening Trial*
Table 2
Correlation matrix for serologic iron indices and dietary iron in CONTROLS ONLY from the PLCO Cancer Screening Trial (n = 396)

The stability of the serum iron parameters over a 6-year period was assessed in a sub-set of incident colorectal adenoma cases and controls (Table 3). Although serum ferritin and TIBC both decreased when comparing the serum samples collected at baseline compared to the serum samples collected at repeat sigmoidoscopy, these changes were not statistically significant (P >0.05). The ICCs in the subgroup of controls with repeat serum measurements showed that ferritin, TIBC, and UIBC levels were stable with all ICCs > 0.7; however, the ICCs for serum iron and transferrin saturation were much lower (0.08 and 0.20, respectively).

Table 3
Medians, interquartile ranges (IQR) for serologic iron indices at two separate time points in a sub-set of incident colorectal adenoma cases (n=50) and controls (n=30) in the PLCO Cancer Screening Trial

In analyses investigating the association between dietary iron sources, serologic indices of iron status and colorectal adenoma incidence, individuals in the highest compared with the lowest quartile of red meat intake had an elevated risk of colorectal adenoma (OR=1.59, 95% CI: 1.02-2.49; P-trend=0.03; Table 4). Although the risks associated with heme iron intake were elevated, they were not statistically significant; whereas the association between total iron intake and colorectal adenoma was null. Serum TIBC and UIBC were inversely associated with colorectal adenoma (OR comparing highest with the lowest quartile of TIBC level [ORq4-q1] = 0.57, 95% CI: 0.37-0.88; P-trend = 0.03 and ORq4-q1=0.62, 95% CI: 0.40-0.95; P-trend=0.04, respectively); both of these serum measures appeared to reveal a threshold effect in the second through fourth quartiles. Serum levels of ferritin, iron and transferrin saturation were not associated with colorectal adenoma incidence (Table 4). These findings did not materially differ by gender or when the outcome was restricted to advanced adenomas (data not shown); furthermore, sub-site specific analyses revealed similar associations for colon versus rectal adenomas.

Table 4
Iron and colorectal adenoma risk in the serologic sample (n=356 cases; n=396 controls) from the PLCO Cancer Screening Trial

In exploratory analyses of serum iron parameter levels by genotypes among the controls in the serologic sample, serum ferritin levels varied according to genotype for four different SNPs in ACO1: IVS1+9689C>T (P =0.004), IVS15-752G>A (P =0.001), IVS15+90A>G (P =0.003), and IVS1+4665C>T (P =0.055); one SNP in TF: IVS11+437C>T (P =0.002); and one SNP in SLC11A2: IVS1-130G>A (P =0.022). Serum iron was higher (P =0.035) in those homozygous for the variant allele for a SNP: Ex6-98T>C in SLC40A1. Serum UIBC was influenced by genotype in SLC11A2 (IVS1-130G>A, P =0.026), TFRC (IVS17+445C>T, P =0.018), and TF (IVS8-318T>G, P =0.006) and TIBC by SNPs in SLC11A2 (Ex16+1142G>A, P =0.045), TF (IVS8-318T>G, P =0.001; IVS11+437C>T, P =0.001), TFRC (IVS17+445C>T, P =0.002), and SLC40A1 (Ex6-98T>C, (P =0.032). However, none of the genotypes or haplotypes were associated with colorectal adenoma risk (Table 5).

Table 5
Distribution of iron-related genotypes and risk of colorectal adenoma (n = 770 cases and 777 controls) in the PLCO Cancer Screening Trial

Discussion

This is the first prospective study to investigate the association of iron exposure with colorectal neoplasia using a heme iron database for the assessment of dietary iron, serum iron indices and variation in multiple genes involved in iron homeostasis. Serum TIBC and UIBC, indicators of low iron stores, were both inversely associated with colorectal adenoma, suggesting that low body iron stores are protective against colorectal adenoma and that iron may play a role in the early stages of colorectal tumorigenesis.

TIBC is commonly assessed in clinical settings as an indicator of iron load and is an indicator of levels of transferrin. Transferrin is the major iron binding and transfer protein in circulation and levels increase as serum iron availability decreases. The association between serum TIBC level and colorectal adenoma incidence was in the expected direction, indicating that as the concentration of transferrin increases (indicative of reduced iron levels), the risk of colorectal neoplasia decreases. Unlike other serum iron indices, such as ferritin, TIBC is not affected by the inflammatory response, and does not exhibit day-to-day variation in measurements (32). UIBC is also a measure of the availability of iron binding sites on transferrin, and also increases as iron availability decreases. Prospective data on TIBC and UIBC in relation to colorectal neoplasia are limited. In contrast to our study, a nested case-control study of women reported no association between TIBC and colorectal adenoma (19), although this was a study of pre-menopausal women, whose serum iron indices could be affected by menstrual cycle phase. The female participants of the current study were almost all post-menopausal, limiting the potential issues of iron loss through menstruation. Another study conducted in men reported a positive association between UIBC and colon cancer (33).

In agreement with our investigation, a nested case-control study of women found no association between serum iron, ferritin, or transferrin saturation in relation to colorectal adenoma (19); whereas a nested case-control study of men found these three serum markers to be inversely related to colon, but not rectal, cancer (33). A potential limiting factor in the assessment of serum iron parameters in relation to colorectal cancer is that circulating iron levels may be affected by bleeding from sub-clinical lesions in the colorectum, which can deplete iron stores (34, 35, 36). Although up to 91% of colorectal cancers bleed, only 6-14% of small adenomas (<10 mm) bleed, increasing to 11-47% of 10-20 mm adenomas, and 20-84% of >20 mm adenomas (34, 37). If iron is positively associated with colorectal neoplasia, such bleeding could bias the association toward the null or even reverse the direction. Given that most colorectal tumors can take more than 10 years to develop (38), it is possible that even prospectively collected blood specimens could be subject to such bias if pre-malignant sub-clinical lesions, such as adenomas, were present. In the current study we sought to address this issue by investigating whether the development of colorectal adenoma is associated with significant temporal changes in iron levels. Although we observed small decreases in median levels of ferritin and TIBC over a 5-year time period, these changes were not statistically significant and were evident in both incident adenoma cases and in the controls who remained polyp-free. This finding suggests that bleeding and consequent iron losses in individuals with sub-clinical colorectal lesions may not be of concern.

The positive association we observed for red meat intake and colorectal adenoma is in agreement with previous studies (1); in addition, calculations of population attributable risks in the large NIH-AARP Diet and Health study cohort estimated that if individuals in the highest quintile of red meat intake adopted intake levels equivalent to those in the first quintile of intake, the colorectal cancer burden would be lowered by 9% (39). One of the hypothesized mechanisms relating red meat to colorectal carcinogenesis is the endogenous formation of NOCs, which is related to heme iron intake (10). Previous studies have attempted to estimate heme iron intake by applying a standard factor to total iron intake from meat. Using such estimations, two studies reported no association between heme iron intake and colorectal adenoma (19) nor cancer (13); whereas two other studies found positive associations within the subgroups of males (12) and proximal colon cancers (14). The heme iron content of meat can not only vary by meat type, but also by cooking method and doneness level (40, 41); therefore, these previous estimations of heme iron likely lead to a substantial degree of error in risk estimates. Our study utilized a unique, newly developed, heme iron database to assign specific heme iron values according to meat type, cooking method and doneness level (24). Despite this improved assessment tool, we did not identify a statistically significant association between heme iron intake and colorectal adenoma incidence. We note, however, that the serologic sample was relatively small and the power to detect modest associations may be limited.

Our study found no evidence for an association between variation in iron metabolism genes and colorectal adenoma, though we did observe significant relationships between several SNPs and serum iron indices-suggesting that circulating iron levels may be influenced by genetic variation in iron uptake and regulatory pathways. Most prior studies that have investigated iron homeostasis genes and colorectal neoplasia have focused on the HFE gene, which is related to the iron overload condition hereditary hemochromatosis. Although a previous study found a relation between SNPs in HFE and colorectal cancer risk, none of the investigations of colorectal adenoma have found such associations, including a study within the PLCO Cancer Screening Trial (18, 19). A limitation of the current study was possible low coverage of variation across the gene regions of interest and hence potential variants associated with colorectal adenoma may have been missed. However, when we subsequently investigated the extent to which our selected SNPs accounted for the total variation within these gene regions in HapMap, the coverage was greater than 75% for all genes except for HP01 and HAMP. In addition, we note that recent genome-wide association studies of colorectal cancer did not reveal any statistically significant relationships between SNPs in iron metabolism gene regions and colorectal cancer, suggesting that germline variation within these genes does not contribute to colorectal tumorigenesis (42).

The advantages of our study included the study of screening detected adenomas, which meant that the cases and controls were asymptomatically selected during a standardized procedure, and being precursor lesions, they were less likely to have been bleeding at the time of the baseline serum collection, which could bias the risk estimates. Furthermore, we used prospectively collected serum samples and dietary data, which included a unique heme iron database to more accurately assess intake of heme iron. We also conducted a small sub-study to evaluate the reliability of a one-time measurement to capture iron parameter levels by comparing serum iron indices in repeat specimens several years apart from the same individual. We found very good agreement for TIBC, UIBC and ferritin; however, the ICCs for iron and transferrin saturation were much lower, indicating that a one-time measurement is not likely to reflect average exposure levels and future investigations may wish to collect data from multiple time points to more accurately assess these factors. Our study also had several caveats, including limited power for detecting associations within genetic subgroups and the use of flexible sigmoidoscopy as the screening method meant that some of the controls could have had proximal adenomas out of reach of detection of the 60cm sigmoidoscope.

To conclude, both TIBC and UIBC were inversely related to colorectal adenoma. These findings are consistent with laboratory data that support a role for iron in the early stages of colorectal tumorigenesis. If real, the iron metabolic pathway may offer a potential route for chemopreventive strategies against colorectal cancer.

Supplementary Material

Acknowledgments

This research was supported by the Intramural Research Program of the Division of Cancer Epidemiology and Genetics and by contracts from the Division of Cancer Prevention, National Cancer Institute, NIH, DHHS.The authors thank Drs. Christine Berg and Philip Prorok, Division of Cancer Prevention, National Cancer Institute, the Screening Center investigators and staff of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, Mr. Tom Riley and staff, Information Management Services, Inc., Ms. Barbara O'Brien and staff, Westat, Inc., Mr. Tim Sheehy and staff, DNA Extraction and Staging Laboratory, SAIC-Frederick, Inc, and Ms. Jackie King and staff, BioReliance, Inc. Most importantly, we acknowledge the study participants for their contributions to making this study possible.

Financial support: This research was supported [in part] by the Intramural Research Program of the National Cancer Institute, National Institutes of Health, Department of Health and Human Services.

Abbreviations

CI
confidence interval
CRP
C-reactive protein
FFQ
food frequency questionnaire
IQR
interquartile range
NOC
N-nitroso compound
NSAID
non-steroidal anti-inflammatory drug
OR
odds ratio
SNP
single nucleotide polymorphism
TIBC
total iron binding capacity
UIBC
unsaturated iron binding capacity

Footnotes

Conflicts of interest: The authors report no conflicts of interest.

References

1. WCRF/AICR. World Cancer Research Fund/ American Institute for Cancer Research. Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective. Washington, D.C.: 2007.
2. Carpenter CE, Mahoney AW. Contributions of heme and nonheme iron to human nutrition. Crit Rev Food Sci Nutr. 1992;31:333–367. [PubMed]
3. Holland B, Welch AA, Unwin ID, Buss DH, Paul AA, Southgate DAT. McCance and Widdowson's The Composition of Foods. Royal Society of Chemistry; Cambridge: 1993.
4. Hallberg L. Bioavailability of dietary iron in man. Annu Rev Nutr. 1981;1:123–147. [PubMed]
5. Lund EK, Wharf SG, Fairweather Tait SJ, Johnson IT. Increases in the concentrations of available iron in response to dietary iron supplementation are associated with changes in crypt cell proliferation in rat large intestine. J Nutr. 1998;128:175–179. [PubMed]
6. Hann HW, Stahlhut MW, Blumberg BS. Iron nutrition and tumor growth: decreased tumor growth in iron-deficient mice. Cancer Res. 1988;48:4168–4170. [PubMed]
7. Siegers CP, Bumann D, Baretton G, Younes M. Dietary iron enhances the tumor rate in dimethylhydrazine-induced colon carcinogenesis in mice. Cancer Lett. 1988;41:251–256. [PubMed]
8. Siegers CP, Bumann D, Trepkau HD, Schadwinkel B, Baretton G. Influence of dietary iron overload on cell proliferation and intestinal tumorigenesis in mice. Cancer Lett. 1992;65:245–249. [PubMed]
9. Taetle R, Rhyner K, Castagnola J, To D, Mendelsohn J. Role of transferrin, Fe, and transferrin receptors in myeloid leukemia cell growth. Studies with an antitransferrin receptor monoclonal antibody. J Clin Invest. 1985;75:1061–1067. [PMC free article] [PubMed]
10. Cross AJ, Pollock JR, Bingham SA. Haem, not Protein or Inorganic Iron, Is Responsible for Endogenous Intestinal N-Nitrosation Arising from Red Meat. Cancer Res. 2003;63:2358–2360. [PubMed]
11. Lijinsky W. Chemistry and biology of N-nitroso compounds. Cambridge University press; Cambridge: 1992.
12. Balder HF, Vogel J, Jansen MC, Weijenberg MP, van den Brandt PA, Westenbrink S, et al. Heme and chlorophyll intake and risk of colorectal cancer in the Netherlands cohort study. Cancer Epidemiol Biomarkers Prev. 2006;15:717–725. [PubMed]
13. Kabat GC, Miller AB, Jain M, Rohan TE. A cohort study of dietary iron and heme iron intake and risk of colorectal cancer in women. Br J Cancer. 2007;97:118–122. [PMC free article] [PubMed]
14. Lee DH, Anderson KE, Harnack LJ, Folsom AR, Jacobs DR., Jr Heme iron, zinc, alcohol consumption, and colon cancer: Iowa Women's Health Study. J Natl Cancer Inst. 2004;96:403–407. [PubMed]
15. Nelson RL. Iron and colorectal cancer risk: human studies. Nutr Rev. 2001;59:140–148. [PubMed]
16. Shaheen NJ, Silverman LM, Keku T, Lawrence LB, Rohlfs EM, Martin CF, et al. Association between hemochromatosis (HFE) gene mutation carrier status and the risk of colon cancer. J Natl Cancer Inst. 2003;95:154–159. [PubMed]
17. van der AD, van der Hel O, Roest M, van der Schouw YT, van Gils CH, Marx JJ, et al. Heterozygosity for the Cys282Tyr mutation in the HFE gene and the risk of colorectal cancer (Netherlands) Cancer Causes Control. 2003;14:541–545. [PubMed]
18. McGlynn KA, Sakoda LC, Hu Y, Schoen RE, Bresalier RS, Yeager M, et al. Hemochromatosis gene mutations and distal adenomatous colorectal polyps. Cancer Epidemiol Biomarkers Prev. 2005;14:158–163. [PubMed]
19. Chan AT, Ma J, Tranah GJ, Giovannucci EL, Rifai N, Hunter DJ, et al. Hemochromatosis gene mutations, body iron stores, dietary iron, and risk of colorectal adenoma in women. J Natl Cancer Inst. 2005;97:917–926. [PubMed]
20. Gohagan JK, Prorok PC, Hayes RB, Kramer BS. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Control Clin Trials. 2000;21:251S–272S. [PubMed]
21. Hayes RB, Sigurdson A, Moore L, Peters U, Huang WY, Pinsky P, et al. Methods for etiologic and early marker investigations in the PLCO trial. Mutat Res. 2005;592:147–154. [PubMed]
22. Prorok PC, Andriole GL, Bresalier RS, Buys SS, Chia D, Crawford ED, et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials. 2000;21:273S–309S. [PubMed]
23. Gunter MJ, Hayes RB, Chatterjee N, Yeager M, Welch R, Schoen RE, et al. Insulin resistance-related genes and advanced left-sided colorectal adenoma. Cancer Epidemiol Biomarkers Prev. 2007;16:703–708. [PubMed]
24. Sinha R, Cross A, Curtin J, Zimmerman T, McNutt S, Risch A, et al. Development of a food frequency questionnaire module and databases for compounds in cooked and processed meats. Mol Nutr Food Res. 2005;49:648–655. [PubMed]
25. Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ. C-reactive protein and the risk of incident colorectal cancer. Jama. 2004;291:585–590. [PubMed]
26. Gunter MJ, Cross AJ, Huang WY, Stanczyk FZ, Purdue MP, Xue X. et al. A Prospective Evaluation of C-reactive Protein Levels and Colorectal Adenoma Development. Cancer Epidemiol Biomarkers Prev. 2011 [PMC free article] [PubMed]
27. Packer BR, Yeager M, Staats B, Welch R, Crenshaw A, Kiley M, et al. SNP500Cancer: a public resource for sequence validation and assay development for genetic variation in candidate genes. Nucleic Acids Res. 2004;32:D528–532. [PMC free article] [PubMed]
28. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263–265. [PubMed]
29. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, et al. The structure of haplotype blocks in the human genome. Science. 2002;296:2225–2229. [PubMed]
30. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet. 2001;68:978–989. [PubMed]
31. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet. 2002;70:425–434. [PubMed]
32. Hawkins RC. Total iron binding capacity or transferrin concentration alone outperforms iron and saturation indices in predicting iron deficiency. Clin Chim Acta. 2007;380:203–207. [PubMed]
33. Cross AJ, Gunter MJ, Wood RJ, Pietinen P, Taylor PR, Virtamo J, et al. Iron and colorectal cancer risk in the alpha-tocopherol, beta-carotene cancer prevention study. Int J Cancer. 2006;118:3147–3152. [PubMed]
34. Macrae FA, St John DJ. Relationship between patterns of bleeding and Hemoccult sensitivity in patients with colorectal cancers or adenomas. Gastroenterology. 1982;82:891–898. [PubMed]
35. Nakama H, Zhang B, Fattah AS, Zhang X. Colorectal cancer in iron deficiency anemia with a positive result on immunochemical fecal occult blood. Int J Colorectal Dis. 2000;15:271–274. [PubMed]
36. Sadahiro S, Suzuki T, Tokunaga N, Mukai M, Tajima T, Makuuchi H, et al. Anemia in patients with colorectal cancer. J Gastroenterol. 1998;33:488–494. [PubMed]
37. Ahlquist DA, Wieand HS, Moertel CG, McGill DB, Loprinzi CL, O'Connell MJ, et al. Accuracy of fecal occult blood screening for colorectal neoplasia. A prospective study using Hemoccult and HemoQuant tests. Jama. 1993;269:1262–1267. [PubMed]
38. Winawer SJ, O'Brien MJ, Waye JD, Kronborg O, Bond J, Fruhmorgen P, et al. Risk and surveillance of individuals with colorectal polyps. Who Collaborating Centre for the Prevention of Colorectal Cancer. Bull World Health Organ. 1990;68:789–795. [PubMed]
39. Cross AJ, Leitzmann MF, Gail MH, Hollenbeck AR, Schatzkin A, Sinha R. A prospective study of red and processed meat intake in relation to cancer risk. PLoS Med. 2007;4:e325. [PubMed]
40. Martinez-Torres C, Leets I, Taylor P, Ramirez J, del Valle Camacho M, Layrisse M. Heme, ferritin and vegetable iron absorption in humans from meals denatured of heme iron during the cooking of beef. J Nutr. 1986;116:1720–1725. [PubMed]
41. Schricker BR, Miller DD. Effects of cooking and chemical treatment on heme and nonheme iron in meat. J Food Sci. 1983;48:1340.
42. Benyamin B, McRae AF, Zhu G, Gordon S, Henders AK, Palotie A, et al. Variants in TF and HFE explain approximately 40% of genetic variation in serum-transferrin levels. Am J Hum Genet. 2009;84:60–65. [PubMed]